Doxercalciferol in Recurrent Pediatric Solid Tumors
A Phase I Study of Doxercalciferol in Recurrent Pediatric Solid Tumors
Descripción general del estudio
Descripción detallada
The Study Drug:
Doxercalciferol is designed to "copy the actions" of Vitamin D without causing blood levels of calcium to be too high.
Study Drug Dose Level:
If you are found to be eligible to take part in this study, you will begin receiving doxercalciferol. The dose you will receive will be based on how many participants have been enrolled before you, and on the safety data that is available. You will remain on the same dose level throughout this study. There will be up to 9 participants enrolled in each group of the same dose. The first group of participants enrolled on this study will be given small doses of doxercalciferol. If no intolerable side effects are experienced, the next group of participants will be enrolled at a higher dose level. This process will continue until researchers find the highest tolerable dose of doxercalciferol, among the 5 dose levels being tested, that can be given without intolerable side effects occurring.
Study Drug Administration:
If you are found to be eligible to take part in this study, you will begin the first "cycle" of the study drug. Each cycle of chemotherapy will last 28 days.
Doxercalciferol will be taken by mouth every day for 28 days.
Study Visits:
Every week during Cycle 1, you will have a physical exam, and urine will be collected for routine tests.
Two (2) times every week while you are on study, blood (about 2 teaspoons) will be drawn for routine tests.
During Cycles 2 and beyond, you will have the following tests and procedures performed:
- Urine will be collected for routine tests.
- ECG and ECHO will be repeated again only if your doctor feels it is necessary.
- You may also have a computed tomography (CT) scan and/or magnetic resonance imaging (MRI) to check the status of the disease.
Length of Study:
You may remain on this study for up to 12 cycles.You will be taken off this study if the disease gets worse or intolerable side effects occur. The study doctor may stop you from taking part in this study at any time if he/she believes it is in your best interest or if you do not follow the study rules.
You can stop participating in this study at any time. Tell the study doctor if you are thinking about leaving the study so that any risks can be reviewed by your study doctor and so that follow-up care and testing can be discussed. The study doctor will tell you how to stop safely.
End-of-Study Visit:
Once you are off-study, you will have an end-of-study visit. At this visit, the following tests and procedures will be performed.
- You will have a physical exam.
- Blood (around 2 teaspoons) and urine will be collected for routine tests.
- You may also have a CT scan and/or MRI to check the status of the disease.
Long-Term Follow-Up:
After the end-of-study visit, you will have a study visit every month for the first year and then once a year for 10 years. At these visits, you will have a physical exam.
You may also have CT scans and/or MRIs every 8 weeks for the 1st 6 months, every 3 months for the next year, then every 6 months for 1 1/2 years, and then at least 1 time a year after that. This will be done to check the status of your disease.
Researchers would like to keep track of your medical condition and some general health information about you through yearly follow-up visits, letters, and/or phone contact, for up to 10 years. More information (such as other treatments and/or disease response) will be collected if follow-up studies show changes in the disease or in your overall health.
If the disease has gotten worse, researchers will keep track of which parts of your body are involved. Researchers will also collect information about any other cancers or major organ problems you might have developed. Keeping in touch with you and checking on your condition will help researchers look at the long-term effects of the study.
This is an investigational study. Doxercalciferol is FDA approved and commercially available for reducing high levels of a hormone in patients undergoing chronic renal dialysis. Its use in this study, for this disease, is investigational.
Up to 24 patients will take part in the study. All will be enrolled at M. D. Anderson.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- UT MD Anderson Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Written and voluntary consent obtained from the patient or their legal guardians.
- Patient must be greater than 2 and less than 26 years old at time of study entry or at time of initial diagnosis
- Patient must have had histologic verification of a solid malignancy at initial diagnosis (excluding brain stem tumors and visual pathway gliomas)
- Patient must have recurrent measurable or evaluable disease after therapy or refractory to conventional therapy with presence of disease confirmed by standard imaging or biopsy
- Must start protocol therapy within two weeks of disease evaluation and determination of eligibility.
- Performance status of >20% on Lansky play scale for subjects <10 years of age, >20% on Karnofsky score for subjects >= 10 years of age
- Patient must have fully recovered to less than or equal to grade 1 from the acute toxic effects of prior therapy, to meet eligibility criteria
- Adequate bone marrow function defined as peripheral absolute neutrophil count (ANC) equal or more than 500/mm^3, Hemoglobin equal or more than 8g/dl, Platelets equal or more than 20,000/mm^3
- Adequate renal function defined as serum creatinine <1.5 X upper limit of normal (ULN) or age adjusted creatinine clearance of >70ml/min/1.73m^2
- Adequate liver function defined as total bilirubin <1.5 X upper limit of normal (ULN) and AST <2 X upper limit of normal (ULN)
- Serum calcium, phosphorus, or PTH levels must be </= to the upper limit of normal age adjusted values per institutional guidelines.
- Urine calcium level must be </= to the upper limit of normal value per institutional guidelines
- Women of childbearing potential must have a negative serum or urine pregnancy test and not be breastfeeding prior to study therapy. Women of childbearing potential must be using an adequate form of contraception to avoid pregnancy during therapy and for at least 4 weeks after the end of study therapy in such a manner that the risk of pregnancy is minimized (Women of childbearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization)
Exclusion Criteria:
- Any past history of urine calcium stones, idiopathic hypercalcemia, hereditary bone disease, or hypercalciuria in the subject
- Concurrent Medications: Patients currently taking digitalis or thiazides are ineligible
- Concurrent Medications: Oral calcium and vitamin D supplements and all homeopathic medications must be discontinued 2 weeks prior to study entry and while on study therapy.
- Use of other anti-tumor therapy, including but not limited to chemotherapy, radiation therapy, immunotherapy, other investigational agents or other biologic therapy, during study therapy, with the exception of palliative radiation therapy to non-index lesions.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Doxercalciferol
|
.05 mcg/kg by mouth daily x 28 Days
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Maximum Tolerated Dose (MTD)
Periodo de tiempo: Continual reassessment method during 28 day cycles, weekly visits for first cycle and monthly for each additional cycle
|
Continual reassessment method during 28 day cycles, weekly visits for first cycle and monthly for each additional cycle
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Peter E. Zage, MD, PhD, M.D. Anderson Cancer Center
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2006-0423
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Tumores sólidos
-
AstraZenecaActivo, no reclutandoAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, cáncer gástrico, de mama y de ovarioEstados Unidos, Francia, Reino Unido, Corea del Sur
Ensayos clínicos sobre Doxercalciferol
-
Genzyme, a Sanofi CompanyTerminadoHiperparatiroidismo secundarioEstados Unidos
-
Mariana MarkellGenzyme, a Sanofi CompanyTerminadoEnfermedad Renal Crónica | Trasplante de riñónEstados Unidos
-
Southeast Renal Research InstituteRetiradoEnfermedad renal en etapa terminal | Calcificación coronaria | Hormona paratiroideaEstados Unidos
-
Genzyme, a Sanofi CompanyTerminadoPsoriasis en placa crónica de moderada a graveEstados Unidos
-
Emory UniversityTerminadoHiperparatiroidismo SecundarioEstados Unidos
-
Duke UniversityGenzyme, a Sanofi CompanyTerminadoInsuficiencia Renal Crónica | Hiperparatiroidismo SecundarioEstados Unidos
-
Genzyme, a Sanofi CompanyTerminadoInsuficiencia renal | Hiperparatiroidismo secundario | Insuficiencia renal cronicaEstados Unidos, Puerto Rico
-
OPKO IP Holdings II, Inc.TerminadoEnfermedad Renal Crónica | Hiperparatiroidismo secundario | Falla renal cronica | Insuficiencia renal cronicaEstados Unidos
-
Genzyme, a Sanofi CompanyTerminadoHiperparatiroidismo secundarioEstados Unidos
-
Genzyme, a Sanofi CompanyTerminadoHiperparatiroidismo secundarioEstados Unidos